Recently, TIL cell therapy leader Iovance Biotherapeutics announced its 2024 performance, with annual revenue reaching $164 million. Among this, the global first approved TIL therapy Amtagvi (Lifileucel) recorded sales of $48.7 million in Q4 2024, with total annual sales reaching $103.6 million.
Amtagvi is the first FDA-approved T-cell therapy for solid tumor indications, receiving approval from the U.S. FDA on February 16, 2024, for the treatment of advanced melanoma patients. It was also recommended as the preferred second-line treatment for cutaneous melanoma in the NCCN guidelines in April 2024. Since its launch, market recognition has continued to rise.
Iovance expects total revenue from Amtagvi in 2025 to be between $450 million and $475 million, with expected gross margins improving over time, potentially surpassing 70% in the coming years.
As of February 26, 2025, Iovance’s cash position is approximately $422 million. The company expects that its current cash and projected product revenue will be sufficient to fund current and planned operations through the second half of 2026.
 |
 |
 |
